The development and deployment of disease-modifying interventions for Parkinson’s disease (PD) have been limited due to a lack of objective, accurate and reliable measures of progression. As such, the adoption of digital technologies has increased in recent years with the intent to overcome the poor sensitivity of conventional rating scales currently used as the gold standard in clinical trials. However, natural history studies incorporating digital motor endpoints in PD are sparse. Excitingly, data recently published from key longitudinal studies reveal cutting-edge evidence demonstrating that digital endpoints of motor progression are more sensitive than conventional clinical scales.
Join Clario, along with their guest speakers, as they discuss the latest research and clinical developments in which wearable sensor detection of progression is impacting the field of Parkinson’s research. The featured speakers will present data from longitudinal progression investigations including the Oxford Quantification in Parkinsonism (OxQUIP)study, the Wearable Assessments in the Clinic and Home in Parkinson’s Disease (WATCH-PD) study and more.
Kristen Sowalsky, PhD, DC, VP, Medical & Scientific Affairs, Precision Motion, Clario
Dr. Kristen Sowalsky is the Vice President of Medical & Scientific Affairs for Precision Motion at Clario. She oversees the scientific advisory, data science and biostatistical services for digital measures of human movement in clinical trials and academic research. Dr. Sowalsky has 18 combined years of experience in industry, academic/clinical research and clinical practice. Her academic achievements include a BS in Kinesiology and Exercise Science from Appalachian State University, a Doctor of Chiropractic from Logan University and a PhD in Applied Neuromechanics from the University of Florida.
Dr. Sowalsky is also a member of the University of Florida Industry Board. Passionate about improving the lives of patients and their families, Dr. Sowalsky aims to advance meaningful digital mobility outcome utilization to inform therapeutic innovation and development.
Chrystalina Antoniades, PhD, Associate Professor of Clinical Neuroscience, University of Oxford
Dr. Chrystalina Antoniades is an Associate Professor of Neuroscience in the Nuffield Department of Clinical Neurosciences and Head of the NeuroMetrology Lab. Her research team is developing novel ways of accurately measuring various functions in patients with neurological disorders, such as Parkinson’s disease and dementia. Their eventual aim is to replace clinical rating scales in both scientific research and everyday practice, with reliable and objective numerical measures. Dr. Antoniades leads the OxQUIP (Oxford QUantification In Parkinsonism) study, with the goal of identifying measures that can detect disease progression over much shorter time periods than is possible at present.
Tairmae Kangarloo, PhD(c), Associate Director, Digital Strategy, Takeda
Tairmae Kangarloo is the Associate Director of Digital Strategy at Takeda. She is a PhD candidate in behavioral neuroscience at Boston University. She has nine years of clinical research experience in both academia and industry where her work has primarily focused on leading the digital strategy for clinical trials in neuroscience. Ms. Kangarloo has authored numerous publications on the use of wearable sensors to capture digital endpoints of mobility, notably from the Wearable Assessments in the Clinic and Home in Parkinson’s Disease (WATCH-PD) study.
Fay Horak, PhD, PT, Chief Scientist, Precision Motion, Clario; Professor of Neurology, Oregon Health & Science University
Dr. Fay Horak PhD, PT, Founder and Scientific Advisor of the Balance Disorders Laboratory, is the Jay Nutt MD Endowed Professor of Neurology and Adjunct Professor of Behavioral Neuroscience & Biomedical Engineering at Oregon Health & Science University. Dr. Horak is a Physical Therapist and Neuroscientist who is known for her research on the neurophysiology of balance and gait disorders. Dr. Horak received a BS degree in Physical Therapy from the University of Wisconsin, an MS in Neurophysiology from the University of Minnesota and a PhD in Neuroscience from the University of Washington in Seattle.
Dr. Horak has over 450 peer-reviewed papers and 51,000 citations based on 40 years of continuous NIH grant funding for her research. As Chief Scientist at APDM of Clario, she helped to develop the novel wireless, wearable technology to quantify mobility and neurological signs in the clinic and daily life.
Who Should Attend?
This webinar will appeal to professionals in the following areas/job titles:
- Clinical Pharmacologists
- Clinical operations (early Phase)
- TA Experts (Parkinson’s/Neuroscience)
- Medical Monitor/Head of Development for Program
- Clinical operations, clinical development, clinical research
- Regulatory affairs
- Clinical monitoring
- Clinical Scientists
- Imaging Scientists
- Protocol Managers
- Clinical Data Managers
What You Will Learn
Attendees will gain insights into:
- How digital endpoints of gait and balance in PD, combined with machine learning, provide more sensitivity to disease progression than the movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS) Part III (or traditional endpoints)
- By capturing a composite score of digital measures of bradykinesia with wearable sensors, a better signal of disease progression can be provided compared to independent measurements
- Future directions of wearable sensor and digital motor endpoints in clinical trials to monitor the progression of neurodegenerative disease
Clario is a leading healthcare research and technology company that generates the richest clinical evidence in the industry. Across decentralized, hybrid and site-based clinical trials, Clario’s deep scientific expertise, global scale and the broadest endpoint technology platform allows our partners to transform lives.